EP0799222A1 - Piperazine 2,5 dione derivatives as modulators of multi-drug resistance - Google Patents
Piperazine 2,5 dione derivatives as modulators of multi-drug resistanceInfo
- Publication number
- EP0799222A1 EP0799222A1 EP95941797A EP95941797A EP0799222A1 EP 0799222 A1 EP0799222 A1 EP 0799222A1 EP 95941797 A EP95941797 A EP 95941797A EP 95941797 A EP95941797 A EP 95941797A EP 0799222 A1 EP0799222 A1 EP 0799222A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dimethoxy
- tetrahydro
- isoquinolyl
- dioxo
- methylbenzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000036457 multidrug resistance Effects 0.000 title claims abstract description 34
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 title description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 32
- -1 methylenedioxy group Chemical group 0.000 claims abstract description 30
- 239000001257 hydrogen Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 7
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical class O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 36
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- UTLVGNQLJMDVES-HWIUFGAZSA-N 3-[(z)-(5-benzyl-4-methyl-3,6-dioxopiperazin-2-ylidene)methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)C1CC1=CC=CC=C1 UTLVGNQLJMDVES-HWIUFGAZSA-N 0.000 claims description 4
- UPXASELIVPAVIA-GPEZSHSTSA-N 3-[(z)-[(5z)-5-benzylidene-4-[2-(dimethylamino)ethyl]-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1CCN(C)C)=O)/NC(=O)\C1=C\C1=CC=CC=C1 UPXASELIVPAVIA-GPEZSHSTSA-N 0.000 claims description 4
- YNVWWCFEGXMQMQ-VANQDGIVSA-N [2-[(z)-[(5z)-5-[[3-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]methylidene]-1-methyl-3,6-dioxopiperazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC=C1OC(C)=O YNVWWCFEGXMQMQ-VANQDGIVSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- UTHDNQZLEUCHCA-JTTISPGVSA-N ethyl 2-[(2z,5z)-2-benzylidene-5-[[3-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]methylidene]-3,6-dioxopiperazin-1-yl]acetate Chemical compound CCOC(=O)CN1C(=O)\C(=C\C=2C=C(C=CC=2)C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)NC(=O)\C1=C\C1=CC=CC=C1 UTHDNQZLEUCHCA-JTTISPGVSA-N 0.000 claims description 4
- CJZQRNWMNZUPTD-LPIHMFRFSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-5-[(3-hydroxyphenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC(O)=C1 CJZQRNWMNZUPTD-LPIHMFRFSA-N 0.000 claims description 4
- VPROFTUUGFZCQL-LPIHMFRFSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-5-[(4-hydroxyphenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=C(O)C=C1 VPROFTUUGFZCQL-LPIHMFRFSA-N 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- GAEOJCDYFMABJF-LPIHMFRFSA-N 2-[(2z,5z)-2-benzylidene-5-[[3-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]methylidene]-3,6-dioxopiperazin-1-yl]acetic acid Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1CC(O)=O)=O)/NC(=O)\C1=C\C1=CC=CC=C1 GAEOJCDYFMABJF-LPIHMFRFSA-N 0.000 claims 2
- VZHRVVBUCDKXIJ-LPIHMFRFSA-N 3-[(Z)-[(5Z)-5-[(2-chlorophenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC(\C=C5/NC(=O)\C(=C\C6=C(Cl)C=CC=C6)N(C)C5=O)=CC=C4)C=C3)CC2)C=C1OC VZHRVVBUCDKXIJ-LPIHMFRFSA-N 0.000 claims 2
- VSWPXILDBNFXIB-YWQXDYITSA-N 3-[(z)-[(5z)-5-(cyclohexylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1CCCCC1 VSWPXILDBNFXIB-YWQXDYITSA-N 0.000 claims 2
- AFSLGMUGRASLRI-LPIHMFRFSA-N 3-[(z)-[(5z)-5-[(3-chlorophenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC(Cl)=C1 AFSLGMUGRASLRI-LPIHMFRFSA-N 0.000 claims 2
- LULGGPSIFKBXMT-CKPXSJKLSA-N 3-[(z)-[(5z)-5-benzylidene-4-(cyclopropylmethyl)-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1CC2CC2)=O)/NC(=O)\C1=C\C1=CC=CC=C1 LULGGPSIFKBXMT-CKPXSJKLSA-N 0.000 claims 2
- LNDHBVSESSZAIU-HSZPEWSQSA-N 3-[(z)-[(5z)-5-benzylidene-4-ethyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound CCN1C(=O)\C(=C\C=2C=C(C=CC=2)C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)NC(=O)\C1=C\C1=CC=CC=C1 LNDHBVSESSZAIU-HSZPEWSQSA-N 0.000 claims 2
- AZDVUUMYSDAHFB-YWQXDYITSA-N 4-[(z)-[(5z)-5-(cyclohexylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1CCCCC1 AZDVUUMYSDAHFB-YWQXDYITSA-N 0.000 claims 2
- NEMWFLYOMMLWMD-XEMPJQOTSA-N [3-[(z)-[(5z)-5-[[3-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]methylidene]-1-methyl-3,6-dioxopiperazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC(OC(C)=O)=C1 NEMWFLYOMMLWMD-XEMPJQOTSA-N 0.000 claims 2
- WZXXNTKUPAIPGW-VANQDGIVSA-N methyl 2-[(2z,5z)-2-benzylidene-5-[[3-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]methylidene]-3,6-dioxopiperazin-1-yl]acetate Chemical compound COC(=O)CN1C(=O)\C(=C\C=2C=C(C=CC=2)C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)NC(=O)\C1=C\C1=CC=CC=C1 WZXXNTKUPAIPGW-VANQDGIVSA-N 0.000 claims 2
- WLFJHNWIUYKMRL-VFHXEFSMSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-3-[(z)-[(5z)-4-methyl-3,6-dioxo-5-(3-phenylpropylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCNC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\CCC1=CC=CC=C1 WLFJHNWIUYKMRL-VFHXEFSMSA-N 0.000 claims 2
- SAWXBWXHBCHTKS-CDSIFPFTSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-3-[(z)-[(5z)-4-methyl-5-(naphthalen-2-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=CC2=CC(/C=C3/C(=O)N\C(C(N3C)=O)=C/C=3C=CC=C(C=3)C(=O)NCCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CC=C21 SAWXBWXHBCHTKS-CDSIFPFTSA-N 0.000 claims 2
- NIHYIHSLXCXAFX-KRFZJYALSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-4-[(z)-[(5z)-4-methyl-3,6-dioxo-5-(3-phenylpropylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCNC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\CCC1=CC=CC=C1 NIHYIHSLXCXAFX-KRFZJYALSA-N 0.000 claims 2
- PAHHHAJAGQAWKP-CDSIFPFTSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-4-[(z)-[(5z)-4-methyl-5-(naphthalen-2-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=CC2=CC(/C=C3/C(=O)N\C(C(N3C)=O)=C/C3=CC=C(C=C3)C(=O)NCCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CC=C21 PAHHHAJAGQAWKP-CDSIFPFTSA-N 0.000 claims 2
- VLGMBRZXBCWLPY-BEORVMNHSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-3,6-dioxo-5-(thiophen-2-ylmethylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CS1 VLGMBRZXBCWLPY-BEORVMNHSA-N 0.000 claims 2
- JVLZNBZOCPFCJN-HEZNUULDSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-3,6-dioxo-5-(thiophen-3-ylmethylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C=1C=CSC=1 JVLZNBZOCPFCJN-HEZNUULDSA-N 0.000 claims 2
- DHHYWFVEXOEYQF-PPUHNOCVSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-3,6-dioxo-5-[[(4s)-4-prop-1-en-2-ylcyclohexen-1-yl]methylidene]piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC[C@@H](C(C)=C)CC1 DHHYWFVEXOEYQF-PPUHNOCVSA-N 0.000 claims 2
- LLHJNNKUEFHGMG-GCEMHJBXSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-3,6-dioxo-5-pentylidenepiperazin-2-ylidene]methyl]benzamide Chemical compound N1C(=O)C(=C/CCCC)/N(C)C(=O)\C1=C\C1=CC=CC(C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)=C1 LLHJNNKUEFHGMG-GCEMHJBXSA-N 0.000 claims 2
- QEGNZHVGNUUXJD-UXNCMSBCSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-5-(2-methylpropylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C1/NC(=O)\C(=C\C(C)C)N(C)C1=O QEGNZHVGNUUXJD-UXNCMSBCSA-N 0.000 claims 2
- UMVDXPFNYQMLDY-PXDBBHOGSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-5-(naphthalen-2-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=CC2=CC(/C=C3/C(=O)N\C(C(N3C)=O)=C/C=3C=CC=C(C=3)C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CC=C21 UMVDXPFNYQMLDY-PXDBBHOGSA-N 0.000 claims 2
- VQVILPCHXGJQTD-RFKWEDMZSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-4-methyl-5-[(1-methylindol-3-yl)methylidene]-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=C2C(/C=C3/C(=O)N\C(C(N3C)=O)=C/C=3C=CC=C(C=3)C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN(C)C2=C1 VQVILPCHXGJQTD-RFKWEDMZSA-N 0.000 claims 2
- LWCNHERLJGRQMD-XREVHHEISA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-5-(3,3-dimethylbutylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C1/NC(=O)\C(=C\CC(C)(C)C)N(C)C1=O LWCNHERLJGRQMD-XREVHHEISA-N 0.000 claims 2
- DJNAGHXXJTWJHR-BEORVMNHSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-5-(furan-2-ylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CO1 DJNAGHXXJTWJHR-BEORVMNHSA-N 0.000 claims 2
- JROAEENSASDNBR-DBNHBIGRSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-3-[(z)-[(5z)-5-[(2-hydroxyphenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC=C1O JROAEENSASDNBR-DBNHBIGRSA-N 0.000 claims 2
- CTGLWZUKIQINSP-PPUHNOCVSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-3,6-dioxo-5-[[(4s)-4-prop-1-en-2-ylcyclohexen-1-yl]methylidene]piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC[C@@H](C(C)=C)CC1 CTGLWZUKIQINSP-PPUHNOCVSA-N 0.000 claims 2
- KRFVGUOETPXRIL-YZUVMVFVSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-3,6-dioxo-5-pentylidenepiperazin-2-ylidene]methyl]benzamide Chemical compound N1C(=O)C(=C/CCCC)/N(C)C(=O)\C1=C\C1=CC=C(C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)C=C1 KRFVGUOETPXRIL-YZUVMVFVSA-N 0.000 claims 2
- HFVUKSFBQDAFSU-QMFFVPNOSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-5-(2-methylpropylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C1/NC(=O)\C(=C\C(C)C)N(C)C1=O HFVUKSFBQDAFSU-QMFFVPNOSA-N 0.000 claims 2
- SMESPBHOCWWGGY-PXDBBHOGSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-5-(naphthalen-1-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=C2C(/C=C3/C(=O)N\C(C(N3C)=O)=C/C3=CC=C(C=C3)C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CC=CC2=C1 SMESPBHOCWWGGY-PXDBBHOGSA-N 0.000 claims 2
- VQHLKPXPSCDSMT-RFKWEDMZSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-5-[(1-methylindol-3-yl)methylidene]-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC=C2C(/C=C3/C(=O)N\C(C(N3C)=O)=C/C3=CC=C(C=C3)C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN(C)C2=C1 VQHLKPXPSCDSMT-RFKWEDMZSA-N 0.000 claims 2
- DUJBVWHCQLBADN-KUPSEYDISA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-5-[(3-methyl-1-benzothiophen-2-yl)methylidene]-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound S1C2=CC=CC=C2C(C)=C1/C=C(N(C)C1=O)/C(=O)N\C1=C/C(C=C1)=CC=C1C(=O)NC(C=C1)=CC=C1CCN1CCC(C=C(C(=C2)OC)OC)=C2C1 DUJBVWHCQLBADN-KUPSEYDISA-N 0.000 claims 2
- NFDHQIXYEYAGQS-RCMCUQTLSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-5-(3,3-dimethylbutylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C1/NC(=O)\C(=C\CC(C)(C)C)N(C)C1=O NFDHQIXYEYAGQS-RCMCUQTLSA-N 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- JWMWQAUZAUFNIN-QASZCPKBSA-N 4-[(z)-[(5z)-4-benzyl-5-benzylidene-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1CC=2C=CC=CC=2)=O)/NC(=O)\C1=C\C1=CC=CC=C1 JWMWQAUZAUFNIN-QASZCPKBSA-N 0.000 claims 1
- QWBAWIVAZGDFRA-LPIHMFRFSA-N 4-[(z)-[(5z)-5-[(2-chlorophenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC=C1Cl QWBAWIVAZGDFRA-LPIHMFRFSA-N 0.000 claims 1
- HHGLBCGKPGBNMG-LPIHMFRFSA-N 4-[(z)-[(5z)-5-[(3-chlorophenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CC(Cl)=C1 HHGLBCGKPGBNMG-LPIHMFRFSA-N 0.000 claims 1
- IBVIZIOPXPHKOB-LPIHMFRFSA-N 4-[(z)-[(5z)-5-[(4-chlorophenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=C(Cl)C=C1 IBVIZIOPXPHKOB-LPIHMFRFSA-N 0.000 claims 1
- JNTMNSPBEBVRSW-CKPXSJKLSA-N 4-[(z)-[(5z)-5-benzylidene-4-(cyclopropylmethyl)-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1CC2CC2)=O)/NC(=O)\C1=C\C1=CC=CC=C1 JNTMNSPBEBVRSW-CKPXSJKLSA-N 0.000 claims 1
- IMNHZHFEHWIUPQ-HSZPEWSQSA-N 4-[(z)-[(5z)-5-benzylidene-4-ethyl-3,6-dioxopiperazin-2-ylidene]methyl]-n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]benzamide Chemical compound CCN1C(=O)\C(=C\C=2C=CC(=CC=2)C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)NC(=O)\C1=C\C1=CC=CC=C1 IMNHZHFEHWIUPQ-HSZPEWSQSA-N 0.000 claims 1
- GJPZEJYOLLPGKQ-PXDBBHOGSA-N N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-5-(naphthalen-1-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound c1c(OC)c(OC)cc(C2)c1CCN2CCc1ccc(NC(=O)c2cccc(c2)\C=c/2c(=O)n(C)c(/c([nH]\2)=O)=C\c2cccc3c2cccc3)cc1 GJPZEJYOLLPGKQ-PXDBBHOGSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QQDGGFKWPHSTIN-PCNBCNDESA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-4-methyl-3,6-dioxo-5-(pyridin-3-ylmethylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CN=C1 QQDGGFKWPHSTIN-PCNBCNDESA-N 0.000 claims 1
- SLWMKVQSKWFTQX-BEORVMNHSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-5-(furan-2-ylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C1=CC=CO1 SLWMKVQSKWFTQX-BEORVMNHSA-N 0.000 claims 1
- RQKXIXWCIZPXKR-HEZNUULDSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-5-(furan-3-ylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1\C=C(C(N1C)=O)/NC(=O)\C1=C\C=1C=COC=1 RQKXIXWCIZPXKR-HEZNUULDSA-N 0.000 claims 1
- KOFZHNHTMVCOKO-VANQDGIVSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-4-[(z)-[(5z)-5-[(4-methoxyphenyl)methylidene]-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1\C=C(/N(C)C\1=O)C(=O)NC/1=C\C1=CC=C(C(=O)NC=2C=CC(CCN3CC4=CC(OC)=C(OC)C=C4CC3)=CC=2)C=C1 KOFZHNHTMVCOKO-VANQDGIVSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 50
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- GKTFLKJXZOYBRW-UHFFFAOYSA-N 2-ethylbenzamide Chemical compound CCC1=CC=CC=C1C(N)=O GKTFLKJXZOYBRW-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 11
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 229960004679 doxorubicin Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- UHDNUPHSDMOGCR-UHFFFAOYSA-N 3-Formylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=O)=C1 UHDNUPHSDMOGCR-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- CBBKKVPJPRZOCM-UHFFFAOYSA-N 1,4-diacetylpiperazine-2,5-dione Chemical compound CC(=O)N1CC(=O)N(C(C)=O)CC1=O CBBKKVPJPRZOCM-UHFFFAOYSA-N 0.000 description 4
- 229940077476 2,5-piperazinedione Drugs 0.000 description 4
- RVUNZHRAYVYUKF-NMGXZBPKSA-N 4-[(Z)-[(5Z)-4-methyl-5-(naphthalen-2-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound [nH]1c(=O)\c(=C\c2ccc3ccccc3c2)n(C)c(=O)\c1=C\c1ccc(C(N)=O)cc1 RVUNZHRAYVYUKF-NMGXZBPKSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 150000004820 halides Chemical group 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- FYDIVWLLJXNXCE-UHFFFAOYSA-N 4-formylbenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C=O)C=C1 FYDIVWLLJXNXCE-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010001986 Amoebic dysentery Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical group 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- FGBGXTYXHYWZDB-APGQMXJTSA-N 2-[(2Z,5Z)-2-benzylidene-5-[(3-carbamoylphenyl)methylidene]-3,6-dioxopiperazin-1-yl]acetic acid Chemical compound c1c(C(=O)N)cccc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)n(CC(O)=O)c1=O FGBGXTYXHYWZDB-APGQMXJTSA-N 0.000 description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
- UDWVMWOKMBEULV-AKEWXQIQSA-N 3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(3-phenylpropylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound Cn1c(=O)\c(=C\c2cc(C(N)=O)ccc2)[nH]c(=O)\c1=C\CCc1ccccc1 UDWVMWOKMBEULV-AKEWXQIQSA-N 0.000 description 2
- VDAPUGOZLLEFKC-RJXAORMISA-N 3-[(Z)-[(5Z)-4-methyl-5-(2-methylpropylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C(C)C)=O)=C/C=1C=C(C(=O)N)C=CC=1)=O VDAPUGOZLLEFKC-RJXAORMISA-N 0.000 description 2
- DWUYSHXAQNMSAI-GUQQWVPNSA-N 3-[(Z)-[(5Z)-4-methyl-5-[(1-methylindol-3-yl)methylidene]-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C1=CN(C2=CC=CC=C12)C)=O)=C/C=1C=C(C(=O)N)C=CC=1)=O DWUYSHXAQNMSAI-GUQQWVPNSA-N 0.000 description 2
- MDZBYUPPSJCSME-RTIOHFMTSA-N 3-[(Z)-[(5Z)-5-(3,3-dimethylbutylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound [nH]1c(=O)\c(=C\CC(C)(C)C)n(C)c(=O)\c1=C\c1cccc(C(N)=O)c1 MDZBYUPPSJCSME-RTIOHFMTSA-N 0.000 description 2
- VZTJYLQNXWWFAE-LSQIQBGYSA-N 3-[(Z)-[(5Z)-5-(cyclohexylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C1CCCCC1)=O)=C/C=1C=C(C(=O)N)C=CC=1)=O VZTJYLQNXWWFAE-LSQIQBGYSA-N 0.000 description 2
- PHFFFHOMYZZDOI-NFZDDIJLSA-N 4-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(3-phenylpropylidene)piperazin-2-ylidene]methyl]benzamide Chemical compound Cn1c(=O)\c(=C\c2ccc(C(N)=O)cc2)[nH]c(=O)\c1=C\CCc1ccccc1 PHFFFHOMYZZDOI-NFZDDIJLSA-N 0.000 description 2
- BTHKPGMIYKRMME-ZLWWWYCESA-N 4-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-[[(4S)-4-prop-1-en-2-ylcyclohexen-1-yl]methylidene]piperazin-2-ylidene]methyl]benzamide Chemical compound C(=C)(C)[C@@H]1CC=C(CC1)\C=C/1\C(N\C(\C(N\1C)=O)=C/C1=CC=C(C(=O)N)C=C1)=O BTHKPGMIYKRMME-ZLWWWYCESA-N 0.000 description 2
- WMMCZIRCHRLFNE-BALBCGQRSA-N 4-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-pentylidenepiperazin-2-ylidene]methyl]benzamide Chemical compound [nH]1c(=O)c(=C/CCCC)/n(C)c(=O)\c1=C\c1ccc(C(N)=O)cc1 WMMCZIRCHRLFNE-BALBCGQRSA-N 0.000 description 2
- VVDPDAVUSPZGDH-NMGXZBPKSA-N 4-[(Z)-[(5Z)-4-methyl-5-(naphthalen-1-ylmethylidene)-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C1=CC=CC2=CC=CC=C12)=O)=C/C1=CC=C(C(=O)N)C=C1)=O VVDPDAVUSPZGDH-NMGXZBPKSA-N 0.000 description 2
- OPFSTIZJTZPSMO-GUQQWVPNSA-N 4-[(Z)-[(5Z)-4-methyl-5-[(1-methylindol-3-yl)methylidene]-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C1=CN(C2=CC=CC=C12)C)=O)=C/C1=CC=C(C(=O)N)C=C1)=O OPFSTIZJTZPSMO-GUQQWVPNSA-N 0.000 description 2
- FKBZRNKLZBSGGE-LSQIQBGYSA-N 4-[(Z)-[(5Z)-5-(cyclohexylmethylidene)-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]benzamide Chemical compound CN\1C(/C(/NC(/C/1=C/C1CCCCC1)=O)=C/C1=CC=C(C(=O)N)C=C1)=O FKBZRNKLZBSGGE-LSQIQBGYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- WJUXOTNINHNDQW-ZAORYEFMSA-N [4-[(Z)-[(5Z)-5-[(3-carbamoylphenyl)methylidene]-1-methyl-3,6-dioxopiperazin-2-ylidene]methyl]phenyl] acetate Chemical compound C(C)(=O)OC1=CC=C(\C=C/2\C(N\C(\C(N\2C)=O)=C/C=2C=C(C(=O)N)C=CC=2)=O)C=C1 WJUXOTNINHNDQW-ZAORYEFMSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 150000003935 benzaldehydes Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- MGFREDWKELGWML-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium;chloride Chemical compound [Cl-].C1=CC=C2C[NH2+]CCC2=C1 MGFREDWKELGWML-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OIWSUFOYSILDHE-UHFFFAOYSA-N 2-(3-bromopropyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCCBr OIWSUFOYSILDHE-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LNRRJKXBZVUZHJ-UHFFFAOYSA-N 3-formylbenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(C=O)=C1 LNRRJKXBZVUZHJ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CQQSQBRPAJSTFB-UHFFFAOYSA-N 4-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-N 0.000 description 1
- NIRCAUPPZAUKDX-UHFFFAOYSA-N 5-benzyl-2-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-6-methylpyridazin-3-one Chemical compound O=C1C=C(CC=2C=CC=CC=2)C(C)=NN1CN(CC1)CCN1C1=CC=CC(Cl)=C1 NIRCAUPPZAUKDX-UHFFFAOYSA-N 0.000 description 1
- SHOWAGCIRTUYNA-UHFFFAOYSA-N 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydron;chloride Chemical compound [Cl-].C1C[NH2+]CC2=C1C=C(OC)C(OC)=C2 SHOWAGCIRTUYNA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002790 naphthalenes Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to compounds useful as modulators of multi-drug resistance (MDR) , to their preparation and to pharmaceutical and veterinary compositions containing them.
- MDR multi-drug resistance
- tumours to treatment with certain cytotoxic agents is an obstacle to the successful chemotherapeutic treatment of cancer patients.
- a tumour may acquire resistance to a cytotoxic agent used in a previous* treatment.
- a tumour may also manifest intrinsic resistance, or cross-resistance, to a cytotoxic agent to which it has not previously been exposed, that agent being unrelated by structure or mechanism of action to any agent used in previous treatments of the tumour.
- certain pathogens may acquire resistance to pharmaceutical agents used in previous treatments of the diseases or disorders to which those pathogens give rise.
- Pathogens may also manifest intrinsic resistance, or cross resistance, to pharmaceutical agents to which they have not previously been exposed. Examples of this effect include multi-drug resistant forms of malaria, tuberculosis, leishmaniasis and amoebic dysentery.
- MDR multi-drug resistance
- P-gp plasma membrane glycoprotein
- Certain agents which have the capacity to modulate MDR may therefore also be useful in facilitating the delivery of drugs across the blood brain barrier, and in treating AIDS and AIDS-related complex.
- RMAs resistance modifying agents
- R x is (i) a group
- each of Ra to Re which may be the same or different, is independently selected from hydrogen, Ci-Cg alkyl unsubstituted or substituted by one or more halogen atoms, C 1 -C 8 alkenyl, C x -Cg alkoxy, C x -C 6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, -CH 2 OH, -CH 2 COOH,
- n is 0 or is an integer of from 1 to 6, each of R 11 and R 12 is independently H or Cj-Cg alkyl and R 13 is C x -C 6 alkyl; or any of Ra and Rb, Rb and Re, Re and Rd or Rd and Re together form a methylenedioxy group, or form together with the carbon atoms to which they are attached a benzene ring which is optionally substituted; (ii) a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from O, N and S, which group may be fused to a benzene ring;
- R 2 is H, C- L -Cg alkyl optionally substituted by a group -N(R 11 R 12 ) as defined above, C 3 -C 6 cycloalkyl, C 2 - C 6 alkenyl, -COOR 11 wherein R 11 is as defined above or a phenyl group as defined under (i) above, but is other than H when R 1 is unsubstituted phenyl; and one of R 3 and R 4 is hydrogen and the other is a group of formula (A) :
- R 5 and R 6 which may be the same or different, are each H or Cj-Cg alkoxy, or R 5 and R 6 together form a methylenedioxy group; and is a double bond or, when R ⁇ is as defined under
- a Ci-Cg alkyl group may be linear or branched.
- a Cj-Cg alkyl group is typically a C ⁇ C ⁇ alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert- butyl group.
- a C 3 -C 6 cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl .
- a halogen is, for example, fluorine, chlorine, bromine or iodine.
- a C j -C 8 alkoxy group is typically a C ⁇ C, alkoxy group, for example a methoxy, ethoxy, propoxy, i-propoxy, n-butoxy, sec-butoxy or tert-butoxy group.
- a C 2 -C 6 alkenyl group is, for example, C 2 -C 4 alkenyl, for example ethenyl, prop-1-enyl or prop-2-enyl.
- a heterocyclic group may be, for example, a pyridine, pyrrole, furan or thiophene group which is linked via any one of its constituent ring atoms. It may be, for instance, a 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, 2- thienyl or 3-thienyl group.
- the integer q is from 1 to 4, and is preferably 1 or 2.
- R 5 and R 6 are preferably the same and are preferably C 1 - C 4 alkyl, for instance methyl.
- the phenyl group is unsubstituted or is substituted at one or more of positions 2 to 6. When it is mono-substituted it may carry the substituent at any one of positions 2 to 6, for instance position 3 or 4, especially position 4.
- one of Ra to Re is other than hydrogen, preferably Rb or Re, especially Re.
- the substituent Ra to Re is preferably selected from a halogen, for instance chlorine, bromine or fluorine; a C j -Cg alkoxy group, for instance OMe; and an acetamido group -NHAc in which Ac denotes acetyl .
- the phenyl group may instead be 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5- disubstituted, or 2,3,4-, 2,3,5-, 2,3,6- or
- Ra to Re When it is disubstituted, three of Ra to Re are hydrogen and two are other than hydrogen.
- Ra and Rb, or Ra and Re, or Ra and Rd, or Ra and Re, or Rb and Re, or Rb and Rd are other than hydrogen whilst, in each case, the other three of Ra to Re are hydrogen.
- Ra to Re When the phenyl group is trisubstituted, two of Ra to Re are hydrogen and three are other than hydrogen.
- Ra, Rb and Re, or Ra, Rb and Rd, or Ra, Rb and Re, or Rb, Re and Rd are other than hydrogen whilst, in each case, the other two of Ra to Re are hydrogen.
- each of Ra to Re is hydrogen.
- one of Ra to Re is selected from hydroxy, alkoxy, NHCOR 11 , -COjR 11 , -N(R 11 R 12 ) , -O(CH 2 ) n N(R X1 R 12 ) , -S0 2 R 13 , -CON R ⁇ R 12 ) , N0 2 , -SO ⁇ R ⁇ R 12 ) , -SOR 13 , -N(R 11 ) COR 12 and halogen and the other four of Ra to Re are H.
- Alkoxy may be, for instance, OMe or OBu n .
- NHCOR 11 is typically -NHAc.
- C0 2 R 1X is typically -COOH or -COOMe.
- NlR ⁇ R 12 ) is typically NMe 2 .
- -CON(R xl R 12 ) may be -CONH 2 .
- S0 2 R 13 is typically S0 2 Me, S0 2 N(R 11 R 12 ) is for example -S0 2 NMe 2 .
- SOR 13 may be SOMe and -N(R lx )COR 12 may be -NMeCOBuX Halogen is typically F or Cl.
- Re is alkoxy, especially OMe or OBu n ; NHCOR 11 , especially -NHAc; -CO-jR 11 , especially -C0 2 H or -C0 2 Me; -CO IR ⁇ R 12 ) especially -CONH 2 ; N0 2 ; N(R"R 12 ) especially NMe 2 ; -SOR 13 especially -SOMe; -S0 2 N(R R 12 ) especially -S0 2 NMe 2 or halogen, especially F or Cl; and each of Ra, Rb, Rd and Re is H.
- Ra to Re are all hydrogen, or one or two of Ra to Re are other than hydrogen whilst the others are hydrogen.
- one of Ra, Rb and Re is other than hydrogen.
- Ra and Re, or Rb and Re are other than hydrogen.
- Preferred values for the one or two of Ra to Re which is or are other than hydrogen include alkoxy such as OMe or OBu n , halogen such as Cl or F, hydroxy, -N(R R 12 ), -C0 2 R n , -CH 2 SCOR 13 , -CH- j SR 11 , -NHCOR 11 , -O(CH 2 ) n N(R X1 R 12 ) , -0(CH 2 ) ⁇ C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R n , -NHCOC ⁇ OR 11 , -NHCOCH 2 OCOR 13 , -CH 2 NHCOOR 13 and CF 3 .
- Particularly preferred compounds are those wherein Ra,
- ⁇ n i WESHEErmua, Rb, Rd and Re are each H, and Re is selected from H, OMe -NHAc, -C0 2 H, -C0 2 Me, -CONH 2 , N0 2 , -NMe 2 , S0 2 Me, -SOMe and -S0 2 NMe 2 .
- Ra to Re are preferably each independently selected from H, halogen, hydroxy, alkoxy, nitro, -CH 2 SCOR 13 , -CH-jSR 11 , -C0 2 R 1X , -OCOR 13 , CF 3 , -0(CH 2 ) n N(R 11 R 12 ) , -O(CH 2 ) n C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R 11 , -NHCO(CH 2 ) n OR", -N(R 11 R 12 ) , -NHCOtCH- n OCOR 11 , -NHCO(CH 2 ) n C0 2 R 11 and -CH 2 NHC0 2 R 13 or Ra and Rb, Rb and Re, Re and Rd, or Rd and Re, form a methylenedioxy group or form, with the carbon atoms to which they are attached, an optionally substituted benzene ring.
- Ra and Rb are independently H, nitro or halogen
- Re is H, hydroxy, -O(CH 2 ) n N(R X1 R 12 ) , -OCOR 13 , -0 ( CR 2 ) n C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R 11 , alkoxy, -NHCO(CH 2 ) n OR 11 , -NHCO(CH 2 ) n OCOR 11 , -N(R 11 R 12 ) ,
- Rd is H, halogen, alkoxy, -CH 2 SCOR 13 , -CHzSR 11 or -COjR 11 ; and Re is H, nitro or halogen.
- R 1 is a phenyl group as defined above which is unsubstituted or mono-substituted at position 2, 3 or 4 by Cl or MeO, or is a pyridyl, furyl or
- R 1 is unsubstituted phenyl
- R 2 is 0* ⁇ 0 4 alkyl, preferably methyl, or is phenyl or cyclopropyl
- R 3 is H
- R" is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO.
- R 1 is substituted phenyl as defined above or a furyl, thienyl or pyridyl group
- R 2 is H
- R 3 is H
- R 4 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO.
- R 1 is substituted phenyl as defined above or a furyl, thienyl or pyridyl group
- R 2 is H
- R 3 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO
- R 4 is H.
- R 1 is unsubstituted phenyl
- R 2 is alkyl, preferably methyl, phenyl or cyclopropyl
- R 3 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO
- R 4 is H.
- R 1 is a furyl, thienyl or pyridyl group it is preferably a 3-furyl, 2-thienyl, 3- thienyl or 4-pyridyl group.
- Examples of preferred compounds of the invention are as follows. The compound numbering is adhered to in the rest of the specification.
- R 7 and R 8 is hydrogen and the other is -CHO, and q, r, R 5 and R 6 are as defined above; in the presence of a base in an organic solvent; and, if desired, converting the resulting compound into a pharmaceutically acceptable salt
- Suitable bases include caesium carbonate, sodium carbonate, potassium carbonate, sodium hydride, potassium t- butoxide and triethylamine.
- Suitable organic solvents include dimethylformamide
- DMF tetrahydrofuran
- THF tetrahydrofuran
- the temperature is typically between 0°C and reflux temperature, for example from 80°C-95°C when caesium carbonate is used as base.
- the reaction mixture is typically warmed from 0°C to room temperature, or to 40°C.
- the reaction may be performed for a period of 1 to 4 hours, for example 2 or 3 hours.
- the compounds of formula (II) wherein is a double bond are prepared by a process which comprises treating a compound of formula (IV) :
- R 1 is as defined above, with an alkylating agent, in an organic solvent in the presence of a base.
- the alkylating agent is typically an alkyl halide R 2 -CH 2 X, a methanesulphonate or p-toluenesulphonate ester R 2 CH 2 OS0 2 Me or R 2 CH 2 OS0 2 C 6 H 4 Me, respectively, or a dialkyl sulphate (R 2 CH 2 0) 2 S0 2 , wherein R 2 is as defined above and X is a halogen, for instance Cl Br or I.
- Suitable bases and solvents include sodium hydride in THF or DMF or mixtures thereof, and potassium t-butoxide in t-butanol or THF or DMF or mixtures thereof.
- the reaction mixture is typically warmed from 0°C to room temperature.
- R 1 is as defined under (i) above and R 2 is as defined above with acetic anhydride.
- the reaction is typically performed under reflux, for instance for 1 to 6 hours, typically 3 hours.
- the compound of formula (X) may be prepared by treating a compound of formula (XI) :
- the compounds of formula (XI) may be prepared by treating a compound of formula (XII) :
- Compounds of formula (IV) may be prepared by a process which comprises treating 1,4-diacetyl-2, 5-piperazinedione of formula (V) :
- R 1 is as defined above, in the presence of a base in an organic solvent .
- Suitable bases and solvents include triethylamine, caesium carbonate, sodium carbonate, potassium carbonate and sodium hydride in DMF or THF or mixtures thereof, and potassium t-butoxide in t-butanol or DMF or THF or mixtures
- the temperature of the reaction is typically from 100-140°C, for instance 120- 130°C.
- potassium t-butoxide is used as base the reaction mixture is typically warmed from 0°C to room temperature.
- the reaction is conducted in an organic solvent either with an excess of the amine of formula (IX) , or in the presence of a base such as a tertiary amine, e.g. Et 3 N, or pyridine.
- the organic solvent is an inert organic solvent such as CH 2 C1 2 .
- the coupling agent used in (a) or (b) with the 3- or 4- formylbenzoic acid, respectively, may be, for instance, 1- cyclohexyl-3- (2-morpholinoethyl) carbodiimide metho-p- toluenesulphonate or 2-chloro-l-methylpyridinium iodide.
- the activated acid halide or mixed anhydride derivative of 3- or 4-formylbenzoic acid may be produced by conventional methods.
- the acid halide derivative may be prepared by treatment of the carboxylic acid with a halogenating agent, for instance a chlorinating agent such as SOCl 2 , PC1 3 , oxalyl chloride or PC1 5 .
- a halogenating agent for instance a chlorinating agent such as SOCl 2 , PC1 3 , oxalyl chloride or PC1 5 .
- the mixed anhydride derivative may be prepared by treatment of the carboxylic acid with a Cj-Cg alkyl haloformate such as iBuOCOCl or EtOCOCl , in the presence of a base such as Et 3 N.
- the reduction step (ii) is typically performed using iron powder and concentrated hydrochloric acid in methanol, usually at a temperature of about 80°C and for a period of 1 to 4 hours, for instance 3 hours. Alternatively it may be carried out by catalytic hydrogenation over a palladium on carbon catalyst in methanolic HCl, isopropanol or acetic acid.
- Suitable salts include salts with pharmaceutically acceptable inorganic or organic acids.
- inorganic acids include hydrochloric acid, sulphuric acid and orthophosphoric acid.
- organic acids include -toluenesulphonic acid, methanesulphonic acid, mucic acid and succinic acid.
- MDR cells which exhibit multi-drug resistance
- MDR cells display a reduction in intracellular drug accumulation compared with the corresponding drug-sensitive cells.
- Studies using jLn vitro derived MDR cell lines have shown that MDR is often associated with increased expression of a plasma membrane glycoprotein (P-gp) which has drug binding properties.
- P-gp plasma membrane glycoprotein
- P-gp is thought to function as an efflux pump for many hydrophobic compounds
- transfection studies using cloned P-gp have shown that its overexpression can confer the MDR phenotype on cells: see, for example, Ann. Rev. Biochem . 58 . 137-171 (1989) .
- P-gp A major function of P-gp in normal tissues is to export intracellular toxins from the cell.
- overexpression of P-gp may play a clinical role in multi-drug resistance.
- Increased levels of P-gp mRNA or protein have been detected in many forms of human cancers - leukaemias, lymphomas, sarcomas and carcinomas. Indeed, in some cases P-gp levels have been found to be increased in tumour biopsies obtained after relapse from chemotherapy.
- Inhibition of P-gp function in P-gp mediated MDR has been shown to lead to a net accumulation of anti-cancer agent in the cells.
- Verapamil a known calcium channel blocker was shown to sensitise MDR cells to Vinca alkaloids .in vitro and jLn vivo: Cancer Res. , 4.1, 1967-1972 (1981) .
- the proposed mechanism of action involves competition with the anti-cancer agent for binding to the P- gp.
- a range of structurally unrelated resistance-modifying agents acting by this mechanism have been described such as tamoxifen (Nolvadex: ICI) and related compounds, and cyclosporin A and derivatives.
- the present compounds have been found in biological tests to have activity in modulating multi-drug resistance. The results are set out in Example 5 which follows.
- the present compounds may therefore be used as multi-drug resistance modifying agents, also termed resistance-modifying agents, or RMAs.
- the present compounds can modulate, e.g. reduce, or eliminate multi-drug resistance.
- the present compounds can therefore be used in a method of potentiating the cytotoxicity of an agent which is cytotoxic to a tumour cell. Such a method comprises, for
- the present compounds can also be used in a method of treating a disease in which the pathogen concerned exhibits multi-drug resistance, for instance multi-drug resistant forms of malaria (Plasmodium falciparum) . tuberculosis, leishmaniasis and amoebic dysentery.
- a method of treating a disease in which the pathogen concerned exhibits multi-drug resistance for instance multi-drug resistant forms of malaria (Plasmodium falciparum) . tuberculosis, leishmaniasis and amoebic dysentery.
- Such a method comprises, for instance, administering one of the present compounds with (separately, simultaneously or sequentially) the drug to which the pathogen concerned exhibits multi-drug resistance.
- the therapeutic effect of the drug may thus be enhanced.
- a human or animal patient harbouring a tumour may be treated for resistance to a chemotherapeutic agent by a method comprising the administration thereto of one of the present compounds.
- the present compound is administered in an amount effective to potentiate the cytotoxicity of the said chemotherapeutic agent.
- chemotherapeutic or antineoplastic agents which are preferred in the context of the present invention include Vinca alkaloids such as vincristine and vinblastine; anthracycline antibiotics such as daunorubicin and doxorubicin; mitoxantrone; actinomycin
- a human or animal patient suffering from a disease in which the responsible pathogen exhibits multi- drug resistance may be treated for resistance to a therapeutic agent by a method comprising the administration thereto of one of the present compounds.
- Examples of such disease include multi-drug resistant forms of malaria (Plasmodium falciparum) , tuberculosis, leishmaniasis and amoebic dysentery.
- Posmodium falciparum multi-drug resistant forms of malaria
- tuberculosis tuberculosis
- leishmaniasis amoebic dysentery.
- MDR modulators also have utility in the delivery of drugs across the blood-brain barrier, and in the treatment of AIDS and AIDS-related complex.
- the present compounds can therefore be used in a method of facilitating the delivery of drugs across the blood brain barrier, and in the treatment of AIDS or AIDS related complex.
- a human or animal patient in need of such treatment may be treated by a method comprising the administration thereto of one of the present compounds .
- the present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously.
- the present compounds may therefore be given by injection or infusion.
- the dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 50 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
- a piperazinedione derivative of formula (I) or a pharmaceutically acceptable salt thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent.
- the compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form.
- An agent for use as a modulator of multi-drug resistance comprising any one of the present compounds is therefore provided.
- the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates.
- diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch
- lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
- the syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol.
- a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose.
- the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol .
- Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride .
- a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride .
- Some of the present compounds are insoluble in water. Such compounds may be encapsulated within liposomes .
- Method B 4-diacetyl-2, 5-piperazinedione was treated with a series of benzaldehydes R ⁇ CHO, where R 1 is as listed in table IB, in the presence of potassium t-butoxide in t- butanol-THF (1:1) at 0°C.
- the reaction mixture was allowed to warm to room temperature for the time indicated in the table. Recrystallisation, which was optional, was conducted using the indicated solvent.
- Method E Compound 1.1, described in Reference Example 1, was treated in DMF with sodium hydride and 2-dimethylaminoethyl chloride hydrochloride at 0°C. The reaction mixture was warmed to 20°C, and then further warmed to 80°C, over a period of 5 hours. The product was purified by recrystallisation from 1% MeOH in EtOAc to give 2.41 in 32% yield, which is a compound of formula (II) wherein R 2 is -CH 2 NMe 2 .
- Method F Compound 1.1, described in Reference Example 1, was treated in acetonitrile with Cs 2 C0 3 and ethyl bromoacetate at -20°C. The reaction mixture was warmed to 20°C for 2 hours. The product was purified by flash chromatography using EtOAc-hexane (1:2) to give 2.42 in 35% yield, which is a compound of formula (II) wherein R 2 is -C0 2 Et.
- 4-formylbenzoyl chloride was prepared by treating 4- formylbenzoic acid with thionyl chloride in toluene under reflux. It was then treated with compound 3.4, prepared according to Reference Example 5, in CH 2 C1 2 in the presence of Et 3 N at a temperature of about 0°C and allowed to warm to room temperature, to afford the following compound 4.2 in 53% yield:
- Example 2 The compounds prepared in Example 2 were converted to the corresponding hydrochloride salts by treatment with gaseous HCI in THF.
- Example 4 Selected compounds prepared in Example 4 were converted to the corresponding hydrochloride salts by treatment with gaseous HCI in CH,Cl 2 .
- the hydrochloride denoted in Table 5 below by the suffix ".HCI” was in some cases then recrystallised as shown in the table.
- Example 7 Pharmaceutical Composition Tablets, each weighing 0.15 g and containing 25 mg of a compound of formula (I) or salt thereof can be manufactured as follows:
- the compound of formula (I) or salt thereof, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) . The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
- Example 8 Testing of compounds of formula (I) and their salts as modulators of MDR
- EMT6 mouse mammary carcinoma cell line and the MDR resistant subline AR 1.0 were cultured in RPMI 1640 medium containing 10% foetal calf serum and 2mM glutamine at 37°C in 5% C0 2 .
- Cells were passaged between 1 in 200 and 1 in 2000 in the case of the parental cell line and between 1 in 20 and 1 in 200 in the case of the MDR resistant subline, after trypsinisation (0.25% trypsin, 0.2gl " ⁇ EDTA) .
- Drug accumulation assay AR 1.0 cells were seeded into 96 well opaque culture plates (Canberra Packard) .
- the assay medium contained a mixture of tritiated Daunorubicin (DNR) , a cytotoxic agent, and unlabelled DNR (0.3 ⁇ Ci/ml; 2 ⁇ M) .
- DNR tritiated Daunorubicin
- Compounds of formula I were serially diluted in assay medium over a range of concentrations from 5 nM to 100 ⁇ M. The cells were incubated at 37°C for 1 hr before washing and determination of cell associated radioactivity. Results are expressed as % maximum accumulation where 100% accumulation is that observed in the presence of the known RMA verapamil at a concentration of 100 ⁇ M or as an IC E0 .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9426224.3A GB9426224D0 (en) | 1994-12-23 | 1994-12-23 | Pharmaceutical compounds |
GB9426224 | 1994-12-23 | ||
PCT/GB1995/003027 WO1996020190A1 (en) | 1994-12-23 | 1995-12-22 | Piperazine 2,5 dione derivatives as modulators of multi-drug resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0799222A1 true EP0799222A1 (en) | 1997-10-08 |
Family
ID=10766589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95941797A Withdrawn EP0799222A1 (en) | 1994-12-23 | 1995-12-22 | Piperazine 2,5 dione derivatives as modulators of multi-drug resistance |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0799222A1 (cs) |
JP (1) | JPH10511384A (cs) |
CN (1) | CN1175253A (cs) |
AU (1) | AU698828B2 (cs) |
BG (1) | BG101602A (cs) |
BR (1) | BR9510410A (cs) |
CA (1) | CA2207500A1 (cs) |
CZ (1) | CZ190097A3 (cs) |
FI (1) | FI972660L (cs) |
GB (1) | GB9426224D0 (cs) |
HU (1) | HUT77943A (cs) |
IL (1) | IL116525A0 (cs) |
NO (1) | NO972937D0 (cs) |
NZ (1) | NZ297847A (cs) |
PL (1) | PL320916A1 (cs) |
SK (1) | SK83697A3 (cs) |
TW (1) | TW358094B (cs) |
WO (1) | WO1996020190A1 (cs) |
ZA (1) | ZA9510909B (cs) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0001531A3 (en) * | 1996-10-18 | 2000-09-28 | Xenova Ltd Slough | Anthranilic acid derivatives as multi drug resistance modulators |
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
KR20010085898A (ko) | 1998-10-08 | 2001-09-07 | 피터 기딩스 | 도파민 d3 수용체 조절제 (정신병 치료제)로서 유용한테트라히드로벤즈아제핀 유도체 |
BR0017067A (pt) * | 2000-01-18 | 2002-10-22 | Nereus Pharmaceuticals Inc | Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto |
AU2001288829A1 (en) | 2000-09-06 | 2002-03-22 | Ap Pharma, Inc. | Degradable polyacetal polymers |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
ATE374767T1 (de) | 2002-08-02 | 2007-10-15 | Nereus Pharmaceuticals Inc | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon |
US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
CN103396372B (zh) * | 2013-08-09 | 2015-05-20 | 中国科学院南海海洋研究所 | 一类2,5-二酮哌嗪衍生物及其制备方法和在制备抗海洋污损生物防除剂中的应用 |
JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 脳腫瘍の治療方法 |
KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
CA2991059C (en) | 2015-07-13 | 2024-01-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin monohydrate polymorphs |
JP2019511565A (ja) | 2016-02-08 | 2019-04-25 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | ツカレゾールまたはそのアナログを含む組成物 |
US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
IL268305B2 (en) | 2017-02-01 | 2024-08-01 | Beyondspring Pharmaceuticals Inc | Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced |
JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001408A1 (en) * | 1992-07-10 | 1994-01-20 | Laboratoires Glaxo S.A. | Anilide derivatives |
GB9217331D0 (en) * | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
-
1994
- 1994-12-23 GB GBGB9426224.3A patent/GB9426224D0/en active Pending
-
1995
- 1995-12-21 ZA ZA9510909A patent/ZA9510909B/xx unknown
- 1995-12-22 SK SK836-97A patent/SK83697A3/sk unknown
- 1995-12-22 CZ CZ971900A patent/CZ190097A3/cs unknown
- 1995-12-22 IL IL11652595A patent/IL116525A0/xx unknown
- 1995-12-22 CA CA002207500A patent/CA2207500A1/en not_active Abandoned
- 1995-12-22 WO PCT/GB1995/003027 patent/WO1996020190A1/en not_active Application Discontinuation
- 1995-12-22 JP JP8520301A patent/JPH10511384A/ja active Pending
- 1995-12-22 NZ NZ297847A patent/NZ297847A/en unknown
- 1995-12-22 AU AU43100/96A patent/AU698828B2/en not_active Ceased
- 1995-12-22 EP EP95941797A patent/EP0799222A1/en not_active Withdrawn
- 1995-12-22 CN CN95197672A patent/CN1175253A/zh active Pending
- 1995-12-22 BR BR9510410-0A patent/BR9510410A/pt not_active Application Discontinuation
- 1995-12-22 FI FI972660A patent/FI972660L/fi unknown
- 1995-12-22 HU HU9800398A patent/HUT77943A/hu unknown
- 1995-12-22 PL PL95320916A patent/PL320916A1/xx unknown
- 1995-12-23 TW TW084113836A patent/TW358094B/zh active
-
1997
- 1997-06-11 BG BG101602A patent/BG101602A/xx unknown
- 1997-06-23 NO NO972937A patent/NO972937D0/no unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9620190A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996020190A1 (en) | 1996-07-04 |
FI972660A7 (fi) | 1997-08-22 |
CA2207500A1 (en) | 1996-07-04 |
NO972937L (no) | 1997-06-23 |
BR9510410A (pt) | 1999-09-08 |
AU4310096A (en) | 1996-07-19 |
FI972660L (fi) | 1997-08-22 |
CN1175253A (zh) | 1998-03-04 |
PL320916A1 (en) | 1997-11-10 |
GB9426224D0 (en) | 1995-02-22 |
IL116525A0 (en) | 1996-03-31 |
ZA9510909B (en) | 1996-08-30 |
JPH10511384A (ja) | 1998-11-04 |
SK83697A3 (en) | 1998-05-06 |
NZ297847A (en) | 1999-04-29 |
NO972937D0 (no) | 1997-06-23 |
HUT77943A (hu) | 1998-12-28 |
FI972660A0 (fi) | 1997-06-19 |
AU698828B2 (en) | 1998-11-05 |
CZ190097A3 (cs) | 1998-01-14 |
BG101602A (en) | 1998-02-27 |
TW358094B (en) | 1999-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0799222A1 (en) | Piperazine 2,5 dione derivatives as modulators of multi-drug resistance | |
DE60132235T2 (de) | Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) | |
US5852018A (en) | Pharmaceutical piperazine compounds | |
NO313591B1 (no) | Antranilinsyrederivater som modulatorer av multimedikamentresistens | |
JP5778297B2 (ja) | 癌治療用のhdac阻害剤としての新規4−アミノ−n−ヒドロキシ−ベンズアミド | |
JP2013506714A (ja) | ピロリジンgpr40モジュレーター | |
JPH10500425A (ja) | 薬学的なジケトピペラジン化合物 | |
EA001280B1 (ru) | Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды | |
US9409864B2 (en) | Sulfonamide TRPA1 receptor antagonists | |
EP0626954A1 (en) | Benzocycloheptenes, benzoxepines and benzothiepines | |
EP0799210B1 (en) | Piperazine-2,5-dione derivatives as modulators of multidrug resistance | |
AU2004285913A1 (en) | 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety | |
HUT53606A (en) | Process for production of chained compositions and medical compositions containing them | |
WO2011130163A1 (en) | Substituted hydroxamic acids and uses thereof | |
Sheppard et al. | 3-(2-(3-Pyridinyl) thiazolidin-4-oyl) indoles, a novel series of platelet activating factor antagonists | |
WO1996020179A1 (en) | Piperazine-2,5-dione derivatives as modulators of multi-drug resistance | |
JPH07505393A (ja) | 非橋渡しビスアリールカルビノール誘導体,組成物および使用法 | |
WO2008022747A1 (en) | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents | |
WO2019082910A1 (ja) | バソプレシン受容体拮抗剤 | |
FI76794B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spirotiazolidindionderivat. | |
US5861400A (en) | Pharmaceutical compounds | |
JPH06122677A (ja) | 光学活性なカルボン酸アミド誘導体 | |
JP3786983B2 (ja) | ピロリジノン誘導体 | |
MXPA03002447A (es) | Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina. | |
GB2324301A (en) | Pharmaceutically-active Piperazinedione Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970714 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19981012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990423 |